Key result
Transcatheter mitral valve implantation was successfully performed in a 72-year-old patient with mitral bioprosthesis degeneration.
Why the study?
TMVI is a less-invasive alternative to surgery in high-risk patients, but it is highly operator-dependent and can involve complications.
Case Report (n=1)
Transseptal TMVI is a feasible and less-invasive alternative for high-risk patients with mitral bioprosthesis degeneration, though highly operator-dependent.
Supports TMVI feasibility in high-risk bioprosthetic degeneration; leaves open need for prospective data on durability and outcomes.
Key Clinical Message: Transcatheter mitral valve implantation (TMVI) is considered a less-invasive approach than open-heart surgery, favored in high-risk patients elected for valve replacement. Although seemingly suitable, this procedure is highly operator-dependent. Abstract: Transcatheter mitral valve implantation (TMVI) is an alternative in high-risk patients. We reported a 72-year-old patient with mitral bioprosthesis degeneration successfully receiving TMVI. The procedure has lower morbidity and mortality rate than the surgical approach but can be accompanied by several complications, especially when conducted by an inexperienced operator.
No takes yet. Share an insight, caveat, or question.
Alizadehasl et al. (2024) conducted a case report in Mitral bioprosthesis degeneration (n=1). Transcatheter mitral valve implantation (TMVI) was evaluated. Transcatheter mitral valve implantation was successfully performed in a 72-year-old patient with mitral bioprosthesis degeneration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: